ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Flipping the Script on LBPs: Creative Biolabs Delivers Game-Changing Analytical Services

By: Get News
The regulatory landscape for live biotherapeutic products (LBPs) continues to evolve, sparking the need for standardized testing, formulation, and rigorous quality control. Creative Biolabs stands as a critical partner in the LBP sector, offering one-stop solutions to help scientists and pharmaceutical companies overcome the challenges of developing these next-gen therapies.

New York, USA - September 18, 2024 - A scientist at Creative Biolabs explains, "These live microorganisms, including bacteria and fungi, offer exciting new approaches to treat various diseases, from gastrointestinal issues like inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) to more complex conditions such as diabetes, depression, and even certain cancers. Recent industry news highlights how LBPs, such as probiotics, are breaking new ground, especially with two LBPs recently receiving U.S. FDA approval—a monumental step forward. However, challenges in standardization, dosing, and safety still exist, pushing the need for specialized services that can handle the complexity of these products."

With expertise ranging from microbial isolation to potency and stability tests, Creative Biolabs' Analytical Development and Qualification Services for LBPs ensure that every product is optimized for clinical success.

Advanced Microbial Isolation and Screening

One of the key elements in the development of LBPs is identifying and isolating the right strains of microorganisms. Creative Biolabs manages advanced techniques that focus on screening microorganisms based on functionality, including antimicrobial activity and immune modulation, ensuring only the most promising candidates move forward in the development pipeline.

"The importance of this service is highlighted by available studies showing that certain microbial strains play crucial roles in modulating the gut microbiota and immune response." The scientist elaborated.

Potency Testing: Ensuring Efficacy

The next big hurdle after isolation in LBP development is confirming that the microorganisms are not just surviving but thriving in their intended therapeutic roles. That is where Creative Biolabs' potency test services come into play to provide detailed insights into the effectiveness of live microorganisms, ensuring that live microorganisms maintain their desired functional properties throughout the production process and after formulation.

Stability Testing: Maintaining Viability

Once the potency is confirmed, ensuring the stability of these microorganisms during storage and transportation is critical. Creative Biolabs tackles the issue head-on with stability testing approaches that assess the stability of live biotherapeutic products under various conditions.

"Industry reports on supply chain challenges in LBP delivery highlighted the need for better stability testing, as improper storage can drastically reduce the efficacy of live biotherapeutics. We employ advanced methodologies to guarantee that LBPs remain viable and effective, giving pharmaceutical companies confidence in the shelf-life and functionality of their products." The scientist added.

Monitoring Microbial Contaminants: Keeping Clean

"Contamination, one of the primary risks in LBP manufacturing, can compromise both the safety and effectiveness of the product," the scientist added, "and thus we've established a microbial contaminant monitoring pipeline to ensure that every step of the LBP development process is free from harmful contaminants."

With new regulatory guidelines and heightened interest in live biotherapeutics, companies are under increasing pressure to meet rigorous standards. Creative Biolabs is not only prepared to meet these challenges but is also setting the bar for excellence in the field. Visit https://live-biotherapeutic.creative-biolabs.com to learn more.

About

Creative Biolabs is leading the charge in developing analytical services that meet the unique challenges of LBPs. Their broad range of offerings, from microbial isolation and potency testing to stability and contaminant monitoring, equips pharmaceutical and biotech companies with the tools they need to bring safe, effective LBPs to market. In 2024, Creative Biolabs' team of dedicated scientists will attend several key industry exhibitions to share the latest advancements in biotech, including:

* September 25th, NIH Research Festival

* October 22nd, BioPharma Drug Discovery Nexus Conference

* November 4th, Annual World ADC San Diego

* December 15th, Antibody Engineering & Therapeutics (US) 2024

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://live-biotherapeutic.creative-biolabs.com



Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.